GAiT is an international resource to facilitate the therapeutic use of immunogenetically matched, clinical-grade new types of stem cells (iPSCs) for the benefit of patients globally. GAiT’s vision is that patients globally will have equity of access to this new generation of iPSC-derived cell therapy products.
GAiT’s mission is to enable the global human community the opportunity to benefit from the new generation of cell therapies by facilitating the development of, and access to, clinical-grade and haplotyped induced pluripotent stem cells for the manufacture of cell therapy products.
- Achieve consensus on donor selection and screening criteria and consent standards.
- Achieve global consensus on manufacturing and quality parameters and standards required to consider an iPSC line to be of clinical grade and develop an external quality assurance scheme to facilitate the development of comparability between centres.
- Gain agreement with regulators in various jurisdictions as to the acceptability of the quality standards proposed.
- Develop a database of clinical grade iPSC lines.
News & Events
The latest from GAiT
A poll has been sent to Industry Members' emails to schedule the first Industry Liaison Committee Meeting in the coming weeks.
#ISCT2021 Breaking News – ISCT and WHO launch CGT nomenclature standards at ISCT 2021!
Find out more: https://mailchi.mp/isctglobal/te-rmplenary-6252360
We shall be updating Participants of the iPSC Quality Assessment Round on the manuscript shortly. A professional statistician re-analysed the amalgamated dataset to fortify the paper.
GAiT is also planning its first Industry Liaisons committee meeting. Internal discussions with GAiT Director / CCRM President & CEO Michael May, to discuss schedule, materials, and format, will take place this week. GAiT will then reach out to Industry members directly.
We appreciate Participants' patience - internal reviewers of the paper were dealing with the COVID-19 response, delaying matters. As agreed, we will allow a final review before submission.
Impact of Previously Unrecognized HLA Mismatches Using Ultrahigh Resolution Typing in Unrelated Donor Hematopoietic Cell Transplantation @NeemaMayor @spellman_s, @AnthonyNolan, @CIBMTR @sophpacz
Confirming the impact of ultra-high resolution #HLA typing
Impact of Previously Unrecognized HLA Mismatches Using Ultrahigh Resolution Typing in Unrelated Donor Hematopoietic Cell Transplantation
PURPOSE Ultrahigh resolution (UHR) HLA matching is reported to result in better outcomes following unrelated donor hem...
We are getting ready to welcome you to #EFI2021
All registered delegates should have received their conference log-in details & virtual delegate bag yesterday afternoon, if you didn’t receive this email contact firstname.lastname@example.org
@BSHI_transplant @EFI_Office @BSHIconference
Attention #ISSCR trainee members! Register before the early registration deadline (23:59 EDT on 21 April), and add the pre-meeting Workshop on Clinical Translation to your cart at no cost. #ISSCR2021 http://ow.ly/tWG650EtfvB @CatalentPharma
GAiT has been reorganizing for the next stage in its growth and development. More ambitious goals necessitated internal reviews, strategic decisions, and system restructuring. Thankfully our operations are now again normalized and we shall now be more communicative with members.
"I think we're ready - I would even say we're waiting," @EMA_News Exec Director Emer Cooke told me when I asked her if the agency is ready for the coming wave of ATMPs. Looking forward to sharing the full #CGMED21 keynote address with attendees next week! https://meetingonthemed.com/